DiaMedica Therapeutics (DMAC) Cash from Operations (2018 - 2026)

DiaMedica Therapeutics (DMAC) has reported Cash from Operations for 9 consecutive years, with -$8.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash from Operations fell 6.61% year-over-year to -$8.1 million; the trailing twelve-month figure through Jun 2026 stood at -$31.6 million (down 23.01% YoY), and the FY2025 full-year result was -$29.1 million, down 31.82% from the prior year.
• Cash from Operations improved to -$8.1 million in Q2 2026 per DMAC's latest filing, from -$9.1 million in the prior quarter.
• Across five years, Cash from Operations topped out at -$2.4 million in Q3 2022 and bottomed at -$9.1 million in Q1 2026.
• Historically, Cash from Operations has averaged -$5.5 million across 5 years, with a median of -$5.1 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Cash from Operations grew 22.49% in 2022, then slumped 103.18% in 2023.
• Over 5 years, Cash from Operations stood at -$2.8 million in 2022, then plunged by 37.82% to -$3.8 million in 2023, then plunged by 68.78% to -$6.4 million in 2024, then fell by 21.23% to -$7.8 million in 2025, then dropped by 3.85% to -$8.1 million in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered -$8.1 million, -$9.1 million, and -$7.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.